Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Loncar Investments,LLC
Posted on: 20 Dec 17

Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a stock index of the top 30 companies developing cancer immunotherapy treatments and discovering new ways to use the body’s immune system to fight cancer.

The Committee has added Idera Pharmaceuticals (Nasdaq: IDRA), Nektar Therapeutics (Nasdaq: NKTR) and Pieris Pharmaceuticals (Nasdaq: PIRS) to the index.

These additions replace Advaxis (Nasdaq: ADXS), Curis (Nasdaq: CRIS) and Syndax Pharmaceuticals (Nasdaq: SNDX).

“Immunotherapy delivered important advances to cancer treatment this year, including gaining first-time FDA approvals to treat types of colorectal, gastric and lung cancers, as well as hepatocellular carcinoma, Merkel cell carcinoma, leukemia and lymphoma,” said Brad Loncar, CEO of Loncar Investments and Chairman of the index committee. “We are proud of the critical roles that our index constituents have played in the advancement of immunotherapy and welcome these three new additions that bring innovative and unique approaches to the field.”

Effective this week, all index holdings have been rebalanced to hold equal weight. The index is rebalanced and reconstituted semi-annually. The next rebalance will occur on June 19, 2018.

Loncar Investments is an official partner of the Cancer Research Institute, the world’s longest running nonprofit organization dedicated exclusively to harnessing the immune system’s power to conquer all cancers. To learn about how to donate to CRI, please visit here.

Why immunotherapy: Cancer immunotherapy has become an important sector in the biotechnology space and is changing the way many cancers are treated. While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system's dynamic nature and the way it can more precisely be tailored to fight a patient's disease.

About the index: The Loncar Cancer Immunotherapy Index is an equal-weighted index of 30 top immunotherapy companies rebalanced and reconstituted on a semi-annual basis. Price and return data are independently calculated on a daily basis by Indxx, LLC. This is a sector index similar to Technology sector indices (Internet, Cyber Security, Robotics, etc.). Sector indices allow investors to track interest areas more precisely than broad indices. Additional information can be found at the index’s dedicated website,

Index provider: Loncar Investments, LLC is committed to making the biotechnology space more approachable to a wider range of investors. The company is principally owned by biotech investor and analyst Brad Loncar. Mr. Loncar manages a biotech-focused family portfolio from his Lenexa, Kan. office. He can be followed on Twitter at @bradloncar and his commentary is available at

View source version on

Business Wire

Last updated on: 20/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.